Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2023-05-02 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings
2023-05-02 English
6-K Filing
Regulatory Filings
2023-05-02 English
Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
Regulatory Filings Classification · 95% confidence The document is a press release dated April 26, 2023, announcing that the first patient has been randomized in the OLINGUITO Phase 3 program for filgotinib in Axial Spondyloarthritis (AxSpA). It details the study design, mentions previous Phase 2 results (TORTUGA), provides background on the disease and the drug, and includes standard forward-looking statements typical of corporate news releases. This format—an initial announcement of clinical trial progress, key data points, and future timelines (topline results expected H2 2025)—is characteristic of an Earnings Release (ER) or a general corporate update, but since it is focused purely on clinical trial progress and not comprehensive financial results for a period, it fits best as a general announcement. Given the options, it is a corporate announcement about a significant development (clinical trial initiation/progress). It is not a full 10-K, AR, IR, or a specific financial filing. It is most closely aligned with an Earnings Release (ER) if the company typically uses this format for major operational updates, or potentially a Regulatory Filing (RNS) if it's a required disclosure. However, the content is a detailed operational/clinical update, which often accompanies or substitutes for a formal Earnings Release in biotech/pharma when discussing pipeline milestones. Since it announces key operational progress and includes contact information for Media/Investor relations, 'ER' (Earnings Release, often used broadly for major operational updates) is a strong candidate, but 'RNS' (Regulatory Filings/General Announcement) is the safest fallback for non-standard financial reports. Given the structure and content (announcing a milestone and providing context), it functions as a major corporate announcement. In many databases, such clinical trial updates are categorized under 'ER' if they are issued around reporting periods, or 'RNS' otherwise. Since it is a specific, non-financial operational update, 'RNS' (Regulatory Filings/General Announcement) is the most appropriate general category for a significant, non-periodic corporate event disclosure that doesn't fit a more specific operational code like CAP or TAR.
2023-04-27 Dutch
Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
Legal Proceedings Report Classification · 99% confidence The document is a press release dated April 26, 2023, announcing the initiation of a Phase 3 clinical program (OLINGUITO) for the drug filgotinib in patients with axial spondyloarthritis (AxSpA). It details study objectives, endpoints, and provides background information on the disease and the drug. This type of announcement, which releases key operational and clinical trial updates outside of mandated periodic financial reports (like 10-K or IR), is characteristic of an Earnings Release (ER) if it contained financial results, or more generally, a significant corporate update. Since it focuses on clinical trial progress and corporate strategy rather than just financial highlights, it fits best as a general corporate announcement. However, given the options, this is a high-level announcement of a significant corporate/R&D event. It is not a full financial report (10-K, IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV. It is a press release announcing R&D progress, which often accompanies or precedes an Earnings Release, but here it stands alone as a major operational update. In the context of the provided definitions, this is a general corporate announcement about R&D progress. Since there isn't a specific 'R&D Update' category, and it's not a short announcement pointing to a full report (RPA), it is classified as a general Regulatory Filing (RNS) as a catch-all for significant, non-financial, non-management change announcements, or potentially an Earnings Release (ER) if this was issued around a reporting period, but ER is defined as 'initial announcement of quarterly/periodical financial results (key highlights only)'. Since this is purely clinical/operational news, RNS is the most appropriate fallback for a significant, non-categorized corporate announcement.
2023-04-27 English
Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting
AGM Information Classification · 99% confidence The document explicitly states that it announces the approval of all resolutions proposed at the 'annual shareholders' meeting (AGM)' held on April 25, 2023. It details specific outcomes like director re-appointments and auditor appointments resulting from the meeting. This content directly relates to the proceedings and outcomes of an Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). The document is an announcement of the results, not the presentation materials themselves, but AGM-R is the most specific category covering AGM outcomes.
2023-04-26 English
Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting
AGM Information Classification · 99% confidence The document is titled "Galapagos' aandeelhouders keuren alle door de Raad van Bestuur voorgestelde besluiten goed op de jaarlijkse aandeelhoudersvergadering" (Galapagos' shareholders approve all resolutions proposed by the Board of Directors at the annual general meeting). It explicitly discusses the approval of resolutions and the reappointment/appointment of board members following the Annual General Meeting (AGM) held on April 25, 2023. This content directly relates to the proceedings and outcomes of the AGM. Therefore, the appropriate classification is AGM Information (AGM-R). The document length is short (2700 chars), but it is a summary of the results, not just an announcement that results are available, making AGM-R more specific than RPA or RNS.
2023-04-26 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.